Innovent Biologics Stock Gross Profit

IVBXF Stock  USD 4.86  0.03  0.62%   
Innovent Biologics fundamentals help investors to digest information that contributes to Innovent Biologics' financial success or failures. It also enables traders to predict the movement of Innovent Pink Sheet. The fundamental analysis module provides a way to measure Innovent Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Innovent Biologics pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Innovent Biologics Company Gross Profit Analysis

Innovent Biologics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

 = 

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Innovent Biologics Gross Profit

    
  2.98 B  
Most of Innovent Biologics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innovent Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Competition

According to the company disclosure, Innovent Biologics reported 2.98 B of gross profit. This is 32.74% higher than that of the Healthcare sector and 213.22% higher than that of the Biotechnology industry. The gross profit for all United States stocks is 89.12% higher than that of the company.

Innovent Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innovent Biologics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Innovent Biologics could also be used in its relative valuation, which is a method of valuing Innovent Biologics by comparing valuation metrics of similar companies.
Innovent Biologics is currently under evaluation in gross profit category among its peers.

Innovent Fundamentals

About Innovent Biologics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Innovent Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innovent Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innovent Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Innovent Pink Sheet

Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.